Senter grants IS subsidy to Prosensa for the collaboration with the Radboud University Nijmegen Medical Centre (RUN-MC) on Myotonic Dystrophy

Leiden, The Netherlands, April 27, 2005 – Prosensa and the UNMC have been granted an Innovation Samenwerkings (IS) grant from Senter. Senter is affiliated to the Ministry of Economic affairs and is responsible for the execution of subsidy, credit and fiscal programs in the field of technology, energy, environment and international collaboration. The Technological grant is a general grants scheme to stimulate R&D co-operation. The projects are appraised and prioritized based on the criteria of co-operation, technological innovation and economic perspective.

‘The grant concerns research in the field of Myotonic Dystrophy type 1 (DM1), the most frequent inheritable muscular dystrophy in adults. Although DM1 is commonly classified as a muscular disorder, the disease is characterized by a variable and very complex manifestation of muscular, brain and endocrine problems, varying in severity and generally progressive with age. Application of Prosensa’s RNA-based therapeutic modalities may open up new avenues for future treatment of disease progression in DM1 patients and allow us to test therapeutic potential for various related genetic disorders that affect muscle and brain’, says Prof. Dr. Be Wieringa of the UNMC.

‘We are extremely happy to have been awarded this grant. It will allow to expand our activities into technology needed to further move toward a viable cure for this terrible disease’, says Gerard Platenburg, Prosensa’s CEO.

link to this press release